Hansoh Brand Guidelines: Lianyungang 1995, a 2019 Hong Kong Listing & Licensed Drugs

Founded in 1995, renamed in 2009, listed in 2019.

Hansoh began in Lianyungang, a port city in the north of Jiangsu province, in 1995. English and Chinese Wikipedia both name its founder as Zhong Huijuan, who chairs the company. Chinese Wikipedia gives the original company name as Jiangsu Hausen Pharmaceutical Group, written 豪森; the company’s own history page lists the 1995 start as the establishment of Lianyungang Haosen Pharmaceutical, an older spelling of the same name.

The company’s timeline shows a generic-drug maker growing product by product. It lists Meifeng, sustained-release cefalexin tablets, in 1997 as its first major product; Gainuo, a vinorelbine injection for cancer treatment, in 1999; its first GMP production workshop in Lianyungang, making oral solid formulations, in 2000; and, in 2001, Zefei, a gemcitabine injection, and Oulanning, olanzapine tablets, which it says gave it its position in oncology and psychiatric medicines. The company says it began work on its own Class 1.1 innovative drugs in 2002.

The name changed in 2009, when the company says it was reorganised as a group under the name Jiangsu Hansoh Pharmaceutical Group. In 2011 it set up a research centre in Shanghai, Shanghai Hansoh BioMedical, and in 2012 it opened an administrative and research centre at its Lianyungang headquarters.

The holding company, Hansoh Pharmaceutical Group Company Limited, listed on the Main Board of the Hong Kong Stock Exchange on 14 June 2019 under the stock code 3692, English Wikipedia says; the Hansoh website also gives 2019 for the listing. English Wikipedia adds that the founder’s family holds a majority of the shares, and that in August 2022 the company was announced as an addition to the Hang Seng Index. The Jiangsu operating company describes itself as the principal subsidiary of the listed group.

Seven innovative drugs and a production base in Lianyungang.

Hansoh says its work centres on oncology, anti-infectives, the central nervous system, metabolic disease and autoimmune disease, and that it has brought seven innovative drugs to market in China. Among them are Ameile (aumolertinib), a lung-cancer drug launched in 2020; Hansoh Xinfu (flumatinib), for chronic myeloid leukaemia, launched in 2019; Fulaimei (polyethylene glycol loxenatide), a once-weekly diabetes injection, also launched in 2019; and Hengmu (tenofovir amibufenamide), for hepatitis B, which reached the market in 2021. The others it names are XINYUE (inebilizumab), Saint Luolai (pegmolesatide) and Mailingda (morinidazole), which it says came to market in 2014. The company also says it has more than 70 clinical trials of innovative drug candidates under way, and more than 700 invention patents granted in China and abroad.

Manufacturing is concentrated at home. The company describes a production base in Lianyungang with two finished-product sites and one site for active ingredients. It says the finished-product site has 18 workshops making tablets, capsules, orally dissolving films, injections in bottles, soft bags and vials, and freeze-dried powders, while the ingredient site has 31 workshops making active ingredients including oncology drugs, sterile ingredients and psychiatric drugs.

The company says its production quality system has been certified by the US Food and Drug Administration, the European Medicines Agency and Japan’s PMDA. Its timeline records that its gemcitabine injection, Zefei, was approved by the FDA in 2013, and that its pemetrexed injection was approved by Japan’s PMDA in 2016.

Its own drugs have started to travel. The company says that in 2025 Ameile, sold in the United Kingdom as Aumseqa, received a marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency, which it describes as the first approval of one of its innovative drugs outside China. In 2026, it says, XINYUE received a third approved indication in China.

How the category presents itself.

Korean and Chinese drug makers tend to introduce themselves through places as much as products. Their annual reports and websites lead with research campuses: new buildings in Shanghai and Suzhou, and the technology district of Pangyo, south of Seoul. Chia Tai Tianqing, for example, says it moved its global research headquarters to Shanghai in 2023, and Hengrui says it opened research offices in Princeton and Basel in 2020.

The pictures inside those reports follow a familiar pattern. White-coated scientists work at screens and fume hoods; long packaging lines carry tablets and vials; and the older companies keep a place for their beginnings, with founders and first factories shown in archive photographs. Several of the businesses in this group began as municipal or state factories decades before they became listed research companies.

Trade fairs are the other stage. The companies take booths at the BIO International Convention in the United States and at the large pharmaceutical fairs in China, where licensing talks with international partners are now a regular part of the business. Hengrui’s July 2025 licensing agreement with GSK is one recent example. In this guide, such deals are named without sums, and any deal not confirmed as completed is described as pending.

The visual identities themselves are mostly corporate and restrained: usually a wordmark in red, blue or green, with photography doing most of the work. Few of these companies publish brand guidelines or official colour values, so the palettes in this guide are our own unofficial interpretations, chosen to sit alongside the companies’ public materials without copying them.

Licences to GSK and Regeneron.

Since 2023 Hansoh has licensed several drug candidates to international companies, keeping the rights for China. In October 2023 it reached an agreement with GSK over HS-20089, an antibody-drug conjugate aimed at the B7-H4 target. In December 2023 the two companies agreed a second exclusive licence, for HS-20093, an antibody-drug conjugate aimed at B7-H3, then in early clinical trials in China for lung cancer, sarcoma and other solid tumours; Pharmaceutical Technology reported on 21 December 2023 that GSK gained the rights everywhere except mainland China, Taiwan, Hong Kong and Macau.

In June 2025 Regeneron agreed to take exclusive rights outside mainland China, Hong Kong and Macau to HS-20094, a GLP-1 and GIP receptor agonist, the trade publication DCAT Value Chain Insights reported in its round-up of 19 June 2025; the candidate was then in a Phase III trial for obesity in China and a Phase IIb study in diabetes, and the agreement was subject to customary closing conditions, including US antitrust clearance.

The company states its core values as “responsibility, integrity, diligence, and innovation,” and its English slogan, used across its website, is “Continuous innovation for better life.”

For a design guide, Hansoh shows how a company that grew on generic cancer and psychiatric drugs presents itself as a research business, with its own branded medicines and licences abroad. Compare Hengrui, another Jiangsu drug maker, and CSPC, another Hong Kong-listed Chinese drug maker. For this guide we use a harbour blue, sage and warm white with a serif, an unofficial interpretation; no product or logo is reproduced.

Keep Hansoh’s identity on hand — save it to a board in the Made Good inspiration library.